Multiple reports highlight the performance of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Mixed sentiments are seen as the company undergoes investigations and faces setbacks such as concerns raised by FDA over its blood cancer therapy trial and allegations of fraudulent price reporting for their eye drug, Eylea, which also posted weaker sales due to inventory impact. Insiders within the company have reportedly sold around US$26m of stocks, possibly signaling caution. Notwithstanding, Regeneron's stock registered impressive performance, with a record high. The company's partnership with Doudna-founded Mammoth for gene editing therapies shows innovation while its upcoming Q1 2024 earnings report is awaited with interest. Regeneron had posted mixed revenues in earlier quarters and faces competitive pressures. Also, the company's decision to defend against DOJ complaint on drug-price manipulation is to be noted. Despite these, some analysts suggest an undervaluation of the company’s stocks, indicating potential for growth.
Regeneron Pharmaceuticals REGN News Analytics from Thu, 02 Nov 2023 07:00:00 GMT to Sun, 09 Jun 2024 13:36:12 GMT -
Rating 1
- Innovation 5
- Information 8
- Rumor -2
